LENZ Therapeutics expands sales force to 15,000 eye care professionals by quarter end as VIZZ adoption accelerates. The company delivered approximately 25,000 paid and filled prescriptions in Q1 2026, generating $1.9 million in net revenue, with $1.7 million from product sales. Management confirmed performance aligned with prior guidance, signaling consistent execution in the competitive eye care market. The aggressive sales force expansion demonstrates confidence in VIZZ market penetration and reflects the company's commitment to scaling distribution channels across the healthcare provider network. Investors should monitor prescription volume trends and revenue growth trajectory in upcoming quarters to assess commercial execution effectiveness.
Post from MarketNews_en
Log in to interact with content.